Letrozol 2.5 - Balkan Pharmaceuticals

Developed by Novartis, letrozole (Femara) emerged in 1997 as an effective anti-estrogen for treating breast cancer, particularly in postmenopausal cases where tamoxifen alone fell short. Its mechanism inhibits aromatase, resulting in high estrogen suppression even at doses as low as 0.5 mg. Besides its medical success, letrozole’s popularity spread to sports, especially bodybuilding, as it mitigates effects like water retention. Nonetheless, users are advised to be cautious, as letrozole’s intensity can impact bone health and mood if taken long-term​.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Letrozol 2.5 by Balkan Pharmaceuticals, consult with your doctor or healthcare professional.